查找临床试验
已按「地中海贫血」检索，对应国际通用词 thalassemia
共找到 66 项正在招募的试验
数据更新于 00:19，每 5 分钟自动同步Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
United States
年龄 18 Years – 70 Years
National Institute of Allergy and Infectious Diseases (NIAID)
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
United States
年龄 2 Months – 55 Years
Paul Szabolcs
Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia
Canada
年龄 1 Year – 18 Years
The Hospital for Sick Children
Β-Thalassemia Treatment with KL003 Cell Injection
China
年龄 3 Years – 35 Years
Kanglin Biotechnology (Hangzhou) Co., Ltd.
European Rare Blood Disorders Platform (ENROL)
Spain
年龄 不限 – 100 Years
Hospital Universitari Vall d'Hebron Research Institute
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
China
年龄 6 Years – 35 Years
Shanghai BDgene Co., Ltd.
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
United States
年龄 6 Months – 21 Years
New York Medical College
Long-term Follow-up Study of BRL-101 for TDT
China
年龄 3 Years – 35 Years
Bioray Laboratories
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
United States、Australia、Belgium、Bulgaria、Canada 等 12 国
年龄 18 Years – 不限
Celgene
A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants
China
年龄 5 Years – 35 Years
First Affiliated Hospital of Guangxi Medical University
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
United States、China、Germany、Greece、India 等 9 国
年龄 6 Years – 17 Years
Celgene
A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
South Korea
年龄 19 Years – 不限
Bristol-Myers Squibb